TY  - EJOU
AU  - Chen, Tiffany 
AU  - Kim, Grace 
AU  - Rahimi, Yekta 
AU  - Kamdar, Monisha 
AU  - Fernandez-Hernandez, Eduardo 
AU  - Woan, Karrune 
AU  - Tam, Eric L. 
AU  - Yaghmour, George 

TI  - Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives
T2  - Oncology Research

PY  - 2026
VL  - 34
IS  - 3
SN  - 1555-3906

AB  - Acute myeloid leukemia (AML) remains a biologically heterogeneous disease with historically limited targeted therapies and poor outcomes. The development of menin inhibitors represents a promising shift, particularly for patients harboring <i>KMT2A</i> rearrangements (<i>KMT2A</i>r) and <i>NPM1</i> mutations (<i>NPM1</i>m). This manuscript reviews the molecular rationale of menin inhibition for aberrant homeobox/myeloid ectopic insertion site 1 (HOX/MEIS1)-driven gene expression and leukemogenesis, clinical trial outcomes, and safety data for menin inhibitors, with a focus on recently FDA-approved revumenib and several other agents in development, ziftomenib (KO-539), bleximenib (JNJ-75276617), and icovamenib (BMF-219). We also focused our discussion on future directions to include resistance mechanisms, biomarker identification and monitoring strategies, and combination therapies. Menin inhibition is now being clinically integrated into relapsed/refractory and frontline treatment settings.
KW  - Menin; menin inhibitor; acute myeloid leukemia (AML); leukemia; revumenib; ziftomenib; bleximenib; icovamenib

DO  - 10.32604/or.2025.072443